Suchergebnisse - "Kazandjian, Dickran"

PubPharm (95)

51

Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients

enthalten in: Blood cancer journal | 2019

von Kazandjian, D. | Hill, E. | Hultcrantz, M. | +10

52

Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma

enthalten in: American Journal of Hematology | 2019

von Rustad, E. | Misund, K. | Bernard, E. | +24

53

Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone : Five-Year Follow-up of a Phase 2 Clinical Trial

enthalten in: JAMA oncology | 2018

von Kazandjian, D. | Korde, N. | Mailankody, S. | +4

54

Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma

enthalten in: Bone marrow transplantation | 2018

von Tageja, N. | Korde, N. | Kazandjian, D. | +10

55

Host-related immunodeficiency in the development of multiple myeloma

enthalten in: Leukemia & lymphoma | 2018

von Dosani, T. | Mailankody, S. | Korde, N. | +13

56

A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making : Multiple Myeloma

enthalten in: Clinical pharmacology and therapeutics | 2018

von Raju, G. | Gurumurthi, K. | Domike, R. | +6

57

Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma

enthalten in: Blood advances | 2017

von Mailankody, S. | Kazandjian, D. | Korde, N. | +21

58

Long Noncoding RNA PURPL Suppresses Basal p53 Levels and Promotes Tumorigenicity in Colorectal Cancer

enthalten in: Cell reports | 2017

von Li, X. | Subramanian, M. | Jones, M. | +26

CommentIn: Noncoding RNA Investig. 2018 Jan;2:. - PMID 30148260

59

Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials : A Meta-analysis

enthalten in: JAMA oncology | 2017

von Blumenthal, G. | Zhang, L. | Zhang, H. | +7

60

Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms

enthalten in: Cancer chemotherapy and pharmacology | 2017

von Sissung, T. | Peer, C. | Korde, N. | +5